Barandun S, Castel V, Makula M F, Morell A, Plan R, Skvaril F
Vox Sang. 1975;28(3):157-75. doi: 10.1111/j.1423-0410.1975.tb02755.x.
Plasmin-treated gamma-globulin of placental origin was tested in clinical and laboratory studies and found to be suitable for intravenous use both for prophylactic and therapeutic purposes. Plasmin treatment of gamma-globulin (IgG) results in proteolytic cleavage of 60-70% of the molecules into Fab and Fc fragments whereas 30-40% of the molecules are plasmin resistant. The antibody spectrum of plasmin-treated gamma-globulin is similar to that of standard gamma-globulin. Catabolic properties of the plasmin-resistant portion of this preparation and of standard gamma-globulin are identical. Plasmin-treated gamma-globulin has no anticomplementary activity and its intravenous administration is well tolerated even by highly sensitive immunodeficient patients.
对胎盘来源的经纤溶酶处理的γ-球蛋白进行了临床和实验室研究，发现其适用于预防和治疗目的的静脉注射。γ-球蛋白（IgG）经纤溶酶处理后，60 - 70%的分子被蛋白水解裂解为Fab和Fc片段，而30 - 40%的分子对纤溶酶具有抗性。经纤溶酶处理的γ-球蛋白的抗体谱与标准γ-球蛋白相似。该制剂中对纤溶酶具有抗性的部分以及标准γ-球蛋白的分解代谢特性相同。经纤溶酶处理的γ-球蛋白没有抗补体活性，即使是高度敏感的免疫缺陷患者静脉注射也能很好耐受。
